| 摘要 |
<p>Treatment for a human or other mammal afflicted with IBS-D, comprising the topical delivery to the intestinal tract of said human or other mammal, preferably the large intestine, of a safe and effective amount of a pharmaceutical composition consisting essentially of the 5-ASA active ingredient and pharmaceutically-acceptable excipients. Said topical delivery is preferably accomplished by the oral administration to said human or other mammal of a delayed-release composition consisting essentially of said 5-ASA active ingredient and a pharmaceutically-acceptable excipient.</p> |
